Immune Pharmaceuticals — EpiCept — Merger or Acquisition (May 2013)
29 slides from Immune Pharmaceuticals's merger presentation, May 22, 2013
Slide 1: Investor Presentation May 2013
Investor Presentation May 2013 Improving Patient Lives Through Targeted Medicine
Slide 2: Forward-Looking Statement
Forward – Looking Statement This presentation contains forward looking statements that involve risks and uncertainties regarding the operations and future results of Immune/EpiCept. You should review the company's filings with the Securities and Exchange Commission, including without limitation the
Slide 3: Immune – EpiCept overview
O IMMUNE – EPICEPT (EPCT:NASDAQ NORDIC, OTCQX) Israel Based US Public Company Focused on Antibody Therapeutics Multiple Phase II Clinical Milestones with Bertilimumab Definitive Merger Agreement signed in Q4 2012 with Closing and Up Listing planned in Q3 2013 Merger Ratio: Immune 81% /EpiCept 19% Pr
Slide 4: A Diversified Portfolio with Multiple Shots on Goal
A Diversified Portfolio with Multiple Shots on Goal Internal Resources Prioritized for Bertilimumab 4 Ready for Phase III Fast Track Phase II Phase II Pre-Clinical AMIKET Chemotherapy Induced Peripheral Neuropathy BERTILIMUMAB Ulcerative Colitis, Crohn’s, Severe Asthma, Orphan Auto-Immune Dermatolog
Slide 5: Eotaxin-1 Regulates Eosinophilic Inflammation
Eotaxin-1 Regulates Eosinophilic Inflammation in Crohn’s Disease, Ulcerative Colitis and Severe Asthma 5
Slide 6: Dose Dependent Biological Activity in Phase I
Dose Dependent Biological Activity in Phase 1 Close to 100% Inhibition Induced Eosinophil Shape Change and Prolonged Effect Safe and Well Tolerated in 101 Subjects/Patients - IV, Nasal and Ocular Administration 6
Slide 7: Crohn's Disease and Ulcerative Colitis Proof of Concept Phase II
Crohn’s Disease and Ulcerative Colitis Proof of Concept Phase II in High Tissue Eotaxin-1 UC Initiated Current therapy in non-responders to first line are anti-TNF mAbs (Humira, Remicade) Significant unmet medical need with lack of sustained response and risk of severe adverse events Eotaxin-1 bioma
Slide 8: Animal Data Support Eotaxin-1 Targeting in IBD
Animal Data Support Eotaxin-1 Targeting in IBD Eotaxin-1 -/- Knock Out mice exhibit reduced colitis associated with decreased eosinophilia when induced with DSS. Rothenberg et al., PNAS, 2000 Anti-CCR3 antibody inhibits inflammation and improves histological remodeling in a mouse model of Crohn’s-li
Slide 9: Targeting Eotaxin-1 with Bertilimumab
Targeting Eotaxin-1 with Bertilimumab Rationale for Phase II in Ulcerative Colitis Supported by Experimental and Clinical Data 9 K.Wilson DDW 2013 Increased Tissue Eotaxin-1 (CCL11) in UC in Correlation with Severity of Disease
Slide 10: Bertilimumab Phase II Ulcerative Colitis Proof of Concept Trial
Bertilimumab Phase II Ulcerative Colitis Proof of Concept Trial Personalized Treatment Based on Eotaxin-1 Tissue Levels Double blind placebo controlled trial in 90 patients 60 on bertilimumab 7mg/kg; 30 on placebo Patients selected based on Mayo UC Score and Eotaxin-1 levels (Wilson NIH study and Go
Slide 11: Bertilimumab Target Profile in UC & CD
Bertilimumab can reduce signs and symptoms and induce remission in patients with moderately to severely active UC or CD who have High EOTAXIN TISSUE LEVELS Bertilimumab Target Profile in UC & CD 11
Slide 12: Targeting Eotaxin-1 in Bullous Pemphigoid
Targeting Eotaxin-1 ( CCL11) in Bullous Pemphigoid A Dermatological Auto-Immune Orphan Disease Up-regulation of CCL11 is associated with activated eosinophils in BP IL-5 and CCL11 both involved in regulation of eosinophils in BP Mepoluzimab ( GSK) initiated Phase II trial in BP in 2012 Bertilimumab
Slide 13: Preclinical Data Support Dermal Indications
Preclinical Data Support Dermal Indications: Bertilimumab Inhibits Dermal Eosinophilia In Primates 13
Slide 14: Bertilimumab: Potential Multiple Clinical Indications
Gastro-Enterology Ulcerative Colitis Crohn’s Disease Dermatology Bullous Pemphigoid (Orphan) Atopic Dermatitis Ophthalmology* Verneal/Atopic Keratoconjunctivitis (VKC/AKC) (Orphan) Age Related Macular Degeneration (AMD) Respiratory Severe Asthma Chronic obstructive pulmonary disease (COPD) Oncology
Slide 15: Bertilimumab Targets Severe Asthma Patients
When Asthma Cannot be Controlled Bertilimumab Targets Severe Asthma Patients with Eosinophilic Inflammation 10% most severe patients not controlled by corticosteroids and bronchodilators in moderate unstable and severe asthma High burden of asthma exacerbations and related hospitalization Clinical r
Slide 16: Bertilimumab Rationale in Moderate Unstable and Severe Asthma
Bertilimumab Rationale in Moderate Unstable and Severe Asthma Eotaxin-1 Levels Correlate with Asthma Disease Severity Bertilimumab Reduces Eosinophil Chemotaxis 16
Slide 17: Omalizumab Down-Regulation of Eotaxin-1
Omalizumab (Xolair®) Down-Regulation of Eotaxin-1 May Explain Anti-Inflammatory and Clinical Benefits 17 Zietkowski et al., Advances in Medical Sciences, 2011
Slide 18: Targeting Eotaxin and/or IL-5 in Severe Asthma
Targeting Eotaxin 1 and/or IL-5 in Severe Asthma Anti-IL-5 mAbs mepoluzimab (GSK) and resiluzimab (Teva) Phase II/III results in moderate unstable and severe eosinophilic asthma have demonstrated effect on most relevant FEV1 and asthma exacerbation clinical end points Potential complementary/synergi
Slide 19: NanomAbs Next Generation Antibody Drug Conjugates
NanomAbs Next Generation Antibody Drug Conjugates/Nano Therapeutics Exclusive worldwide license from Hebrew University of Jerusalem Potential advantages over SGEN/IMGN ADC technology include higher payload and drug versatility Three recent $200M pre-clinical stage partnerships with similar technolog
Slide 20: NanomAbs' Advantages: Improved Therapeutic Index
NanomAbs’ Advantages: Improved Therapeutic Index for Chemotherapeutics mAb Driven Endocytosis Maximized Chemotherapy Drug Accumulation into Tumor Cells TUMOR TISSUE TARGETING NanomAbs preferential uptake into tumoR issue based on the enhanced permeability and retention effect A B C TUMOR CELL TARGET
Slide 21: Crolibulin NCI Presents Phase I Data
Crolibulin NCI Presents Phase I Data in Combination with Cisplatin TNFR Survival Factors RB Cyclin D/ CDK2,4,5 Bcl-xl Cyclin E/CDK2 Cyclin A/CDK2 Cyclin A/B/ CDK2 FasL IkB RTKs Ras Raf MEKK JNK/SAPK Fos/Jun Heterodimers TRAF IKK1/ IKK2 inactive complex Calcineurin PI3K Akt Bad Smac/Diablo IAP/Hsp70
Slide 22: AmiKet Phase III Ready with Fast Track for CIPN
AmiKet™ Phase III Ready with Fast Track for CIPN Topical cream for the relief of pain associated with well known neuropathies, CIPN, PHN, DPN Twice daily application of 4% amitriptyline plus 2% ketamine combination provides pain relief equivalent to current therapies Over 1,700 patients treated in n
Slide 23: An Experienced Combined Management Team
An Experienced Combined Management Team Executing an Ambitious Vision Daniel Teper, PharmD, MBA Chief Executive Officer Novartis, GSK, Sanofi, Bionest Suzy Jones Chief Business Development Officer Genentech, DNA Ink Robert Cook Chief Financial Officer Chase, GE, Pharmos, EpiCept Michal Ayalon-Soffer
Slide 24: Active Governance by Board of Directors
Active Governance by Board of Directors Herve de Kergrohen,MD,MBA Board Director UBS, Bellevue, Lombard Isaac Kobrin, MD Board Director, Roche, Actelion Daniel Teper, PharmD, MBA Chairman Novartis, GSK, Sanofi, Bionest David Sidransky, MD, PhD Vice Chairman Imclone, Rosetta, Johns Hopkins Pierre Alb
Slide 25: Unaudited Pro Forma Balance Sheet
Unaudited Pro Forma Balance Sheet As of December 31, 2012 25 Pro Forma Pro Forma Immune EpiCept Adjustments Combined Assets Current assets Cash and cash equivalents 94,951 $ 172,075 $ 267,026 $ Restricted cash and cash equivalents 83,424 909,299 992,723 Prepaid expenses & other current assets 21,415
Slide 26: Unaudited Pro Forma Statement of Operations
Unaudited Pro Forma Statement of Operations 12 Months through December 31, 2012 26 Pro Forma Pro Forma Immune EpiCept Adjustments Combined Revenue - $ 7,804,308 $ (5,137,065) $ 2,667,243 $ Operating expenses: COGS - 402,765 402,765 Selling, general and administrative 1,486,451 4,196,876 5,683,327 Re
Slide 27: Pro Forma Stock Ownership
Pro Forma Stock Ownership As of May 10, 2013 27 Name of Beneficial Owner Following the Merger Number of Shares To Be Beneficially Owned Percent of Shares To Be Beneficially Owned(1) 5% Stockholders Melini Capital 1,190,787 9.88% Dr. Jean Elie Kadouche 842,033 7.26% Serge Goldner 1,065,496 8.68% iCo
Slide 28: Immune/EpiCept Merger Highlights
Immune/EpiCept Merger Highlights Immune/EpiCept merger provides opportunities for Shareholders: To realize value from current EpiCept pipeline and to participate in the significant growth opportunity of the Immune pipeline Liquidity on Nasdaq or NYSE MKT at competitive valuation Access to growth cap
Slide 29: Contact information
Contact information www.immunepharmaceuticals.com Dr. Daniel Teper, CEO, IMMUNE Pharmaceuticals [email protected] Robert Cook, CEO, EpiCept Corporation [email protected] 29